MedTrace Logo

Effect of MAXOMAT ® on the Growth of Small Children to NOONAN's Syndrome

NCT00452725 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2010-10-05

No results posted yet for this study

Summary

1. Clinical Objective : To improve the growth of these children
2. Genetic objective : A study of the genetics of the syndrome

Conditions

  • Noonan Syndrome

Interventions

DRUG

MAXOMAT ®, biosynthetic growth hormone

2 posologies according to age (children and adolescents) treatment is planned for a 2 year duration

Sponsors & Collaborators

Principal Investigators

  • Marie SEBILLE · Sanofi

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Max Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-10-31
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00452725 on ClinicalTrials.gov